Biochem/physiol Actions
A BH3 mimetic that targets MCL-1 with high affinity and selectivity. Selectively inhibits cancer survival in a MCL-1-dependent manner.
A-1210477 is a BH3 mimetic that targets MCL-1 with high affinity (Ki = 0.43 nM) and selectivity (Ki >0.66 μM for BCL-2, BCL-XL, BCL-W, and A1), exhibiting little to no activity toward panels of 80 kinases (IC50 >8.5 μM) and 21 GPCRs (IC50 & EC50 >10 μM). A-1210477 selectively inhibits the survival of MCL-1-dependent (IC50 ~4 μM/multiple myeloma H929, 5.3 μM/NSCLC H2110, 7.2 μM/NSCLC H23), but not BCL-2-dependent RS4;11, cultures via apoptosis induction and potentiates BCL-2/BCL-XL inhibitor ABT-263 (Navitoclax) killing in a variety of cancer cell cultures where ABT-263 alone is ineffective. A-1210477 is also shown to cause cellular MCL-1 upregulation, most likely due to blocking MCL-1 interaction with BH3-only proteins such as NOXA and MULE known to mediate MCL-1 ubiquitylation for proteasomal degradation.
| Quality Segment | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear |
| storage temp. | −20°C |
| SMILES string | O=C(O)C(N1CCN2CCOCC2)=C(C3=C1C(C4=C(N(N=C4C)C)COC5=CC=C(C=C5)N6CCN(CC6)S(=O)(N(C)C)=O)=CC=C3)CCCOC7=C8C=CC=CC8=CC=C7.[H]Cl |
| InChI key | MRLDHNSBXWSDDL-UHFFFAOYSA-N |
